RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Shin Nippon Biomedical Laboratories P/E 2024

Shin Nippon Biomedical Laboratories P/E

10.35

Shin Nippon Biomedical Laboratories Dividend yield

2.18 %

Ticker

2395.T

ISIN

JP3379950003

WKN

A0BMJN

As of May 18, 2024, Shin Nippon Biomedical Laboratories's P/E ratio was 10.35, a -37.23% change from the 16.49 P/E ratio recorded in the previous year.

The Shin Nippon Biomedical Laboratories P/E history

Shin Nippon Biomedical Laboratories Aktienanalyse

What does Shin Nippon Biomedical Laboratories do?

Shin Nippon Biomedical Laboratories Ltd (SNBL) is a Japanese company that was founded in 1957. The company is headquartered in Tokyo, Japan. SNBL is an important player in the research and development industry, offering a wide range of services in the field of biomedical research. SNBL's business strategy is based on providing services to pharmaceutical companies and other medical institutions. The service portfolio includes both the development phase and the approval and post-marketing monitoring of drugs. SNBL offers a comprehensive service in this area, ranging from experimental planning to study implementation, report creation, and results analysis. The company has several geographical offices in Asia, Europe, and America to serve its customers worldwide. SNBL is divided into different divisions specializing in different areas of biomedical research. One important division is the Non-human Primates (NHP) research program. SNBL is able to provide a wide range of NHP species for research, ranging from rhesus monkeys to monkeys from China and Africa. These animals are used for research projects both for drug safety assessment and disease exploration. SNBL is also active in the field of genetic engineering, offering a wide range of services in this area. The company has several cell-based assay systems for drug development and experience in producing recombinant proteins for research. SNBL also offers analysis services for nucleic acids and proteins of all kinds and has extensive expertise in genotyping and gene expression analysis. Another pillar of SNBL's activities is toxicology and safety research. SNBL is a leading provider of toxicology studies, advising its clients on the design of animal safety assessment studies. The company also provides a wide range of non-GLP studies for toxicity evaluations. Additionally, SNBL is able to evaluate the results of toxicology studies and conduct risk analyses for specific products. SNBL also has its own drug development pipeline and has several products in development. One example is Nafamostat Mesilate, a drug being developed for the treatment of acute respiratory distress syndrome and acute pancreatitis. The company works closely with its clients to develop customized solutions for their specific research needs. SNBL's products and services make a significant contribution to the biomedical research industry and have worldwide impact on the healthcare of humans and animals. The company has a long history in the research industry and is recognized as a provider of services for drug development due to its expertise and experience. With its extensive services for biomedical research, SNBL will remain an important player in this field in the future. Shin Nippon Biomedical Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Shin Nippon Biomedical Laboratories's P/E Ratio

The Price to Earnings (P/E) Ratio of Shin Nippon Biomedical Laboratories is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Shin Nippon Biomedical Laboratories's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Shin Nippon Biomedical Laboratories is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Shin Nippon Biomedical Laboratories’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Shin Nippon Biomedical Laboratories Stock

What is the price-to-earnings ratio of Shin Nippon Biomedical Laboratories?

The price-earnings ratio of Shin Nippon Biomedical Laboratories is currently 10.35.

How has the price-earnings ratio of Shin Nippon Biomedical Laboratories changed compared to last year?

The price-to-earnings ratio of Shin Nippon Biomedical Laboratories has increased by -37.23% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Shin Nippon Biomedical Laboratories high compared to other companies?

Yes, the price-to-earnings ratio of Shin Nippon Biomedical Laboratories is high compared to other companies.

How does an increase in the price-earnings ratio of Shin Nippon Biomedical Laboratories affect the company?

An increase in the price-earnings ratio of Shin Nippon Biomedical Laboratories would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Shin Nippon Biomedical Laboratories affect the company?

A decrease in the price-earnings ratio of Shin Nippon Biomedical Laboratories would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Shin Nippon Biomedical Laboratories?

Some factors that influence the price-earnings ratio of Shin Nippon Biomedical Laboratories are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Shin Nippon Biomedical Laboratories pay?

Over the past 12 months, Shin Nippon Biomedical Laboratories paid a dividend of 30 JPY . This corresponds to a dividend yield of about 2.18 %. For the coming 12 months, Shin Nippon Biomedical Laboratories is expected to pay a dividend of 39.34 JPY.

What is the dividend yield of Shin Nippon Biomedical Laboratories?

The current dividend yield of Shin Nippon Biomedical Laboratories is 2.18 %.

When does Shin Nippon Biomedical Laboratories pay dividends?

Shin Nippon Biomedical Laboratories pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Shin Nippon Biomedical Laboratories?

Shin Nippon Biomedical Laboratories paid dividends every year for the past 9 years.

What is the dividend of Shin Nippon Biomedical Laboratories?

For the upcoming 12 months, dividends amounting to 39.34 JPY are expected. This corresponds to a dividend yield of 2.86 %.

In which sector is Shin Nippon Biomedical Laboratories located?

Shin Nippon Biomedical Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shin Nippon Biomedical Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shin Nippon Biomedical Laboratories from 6/1/2024 amounting to 30 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.

When did Shin Nippon Biomedical Laboratories pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Shin Nippon Biomedical Laboratories in the year 2023?

In the year 2023, Shin Nippon Biomedical Laboratories distributed 50 JPY as dividends.

In which currency does Shin Nippon Biomedical Laboratories pay out the dividend?

The dividends of Shin Nippon Biomedical Laboratories are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shin Nippon Biomedical Laboratories

Our stock analysis for Shin Nippon Biomedical Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shin Nippon Biomedical Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.